Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616211 · ClinicalTrials.gov registry record
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 15
- Enrollment target
NCT02616211: Completed study, sponsored by Mayo Clinic.
NCT02616211 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02616211 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616211
The ClinicalTrials.gov registry entry for NCT02616211 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02616211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616211 about?
NCT02616211 is a clinical study titled "An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors". Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response o...
What is the current status of trial NCT02616211?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2014-10. Estimated completion is 2019-12.
Who is sponsoring clinical trial NCT02616211?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.